Stockreport

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Adicet Bio, Inc.  (ACET) 
Last adicet bio, inc. earnings: 5/3 05:00 pm Check Earnings Report
US:NASDAQ Investor Relations: aceto.com/ir/index.html
PDF ADI-270 is the first gamma delta 1 CAR T candidate to enter clinical development for solid tumorsPhase 1 clinical study to evaluate safety and anti-tumor activity of ADI [Read more]